These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24788034)

  • 1. Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012.
    Palladino C; Briz V; Bellón JM; Climent FJ; de Ory SJ; Mellado MJ; Navarro ML; Ramos JT; Taveira N; de José MI; Muñoz-Fernández MÁ;
    PLoS One; 2014; 9(5):e96307. PubMed ID: 24788034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.
    Wamalwa DC; Obimbo EM; Farquhar C; Richardson BA; Mbori-Ngacha DA; Inwani I; Benki-Nugent S; John-Stewart G
    BMC Pediatr; 2010 May; 10():33. PubMed ID: 20482796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
    Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
    Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
    Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
    AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of first-line antiretroviral therapy failure in HIV-infected Thai children and adolescents.
    Bunupuradah T; Sricharoenchai S; Hansudewechakul R; Klinbuayaem V; Teeraananchai S; Wittawatmongkol O; Akarathum N; Prasithsirikul W; Ananworanich J;
    Pediatr Infect Dis J; 2015 Mar; 34(3):e58-62. PubMed ID: 25478649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.
    Oliveira R; Krauss M; Essama-Bibi S; Hofer C; Robert Harris D; Tiraboschi A; de Souza R; Marques H; Succi R; Abreu T; Della Negra M; Hazra R; Mofenson LM; Siberry GK;
    Clin Infect Dis; 2010 Dec; 51(11):1325-33. PubMed ID: 21039218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.
    Yuan Y; L'italien G; Mukherjee J; Iloeje UH
    HIV Med; 2006 Apr; 7(3):156-62. PubMed ID: 16494629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire.
    Fassinou P; Elenga N; Rouet F; Laguide R; Kouakoussui KA; Timite M; Blanche S; Msellati P
    AIDS; 2004 Sep; 18(14):1905-13. PubMed ID: 15353976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment for children.
    Eley B; Davies MA; Apolles P; Cowburn C; Buys H; Zampoli M; Finlayson H; King S; Nuttall J
    S Afr Med J; 2006 Sep; 96(9 Pt 2):988-93. PubMed ID: 17077930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
    Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
    AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
    Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.